Correction: Modulation of serotonin in the gut-liver neural axis ameliorates the fatty and fibrotic changes in non-alcoholic fatty liver

Correction: Modulation of serotonin in the gut-liver neural axis ameliorates the fatty and fibrotic changes in non-alcoholic fatty liver

Bibliographic Details
Main Authors:	Masayoshi Ko, Kenya Kamimura, Takashi Owaki, Takuro Nagoya, Norihiro Sakai, Itsuo Nagayama, Yusuke Niwa, Osamu Shibata, Chiyumi Oda, Shinichi Morita, Atsushi Kimura, Ryosuke Inoue, Toru Setsu, Akira Sakamaki, Takeshi Yokoo, Shuji Terai
Format:	Article
Language:	English
Published:	The Company of Biologists 2023-12-01
Series:	Disease Models & Mechanisms
Online Access:	http://dmm.biologists.org/content/16/12/dmm050622

Similar Items

Modulation of serotonin in the gut-liver neural axis ameliorates the fatty and fibrotic changes in non-alcoholic fatty liver
by: Masayoshi Ko, et al.
Published: (2021-03-01)

Involvement of the liver-gut peripheral neural axis in nonalcoholic fatty liver disease pathologies via hepatic HTR2A
by: Takashi Owaki, et al.
Published: (2022-07-01)

Daisaikoto improves fatty liver and obesity in melanocortin-4 receptor gene-deficient mice via the activation of brown adipose tissue
by: Shinichi Morita, et al.
Published: (2022-06-01)

RETRACTED: Effect of a neural relay on liver regeneration in mice: activation of serotonin release from the gastrointestinal tract
by: Ryosuke Inoue, et al.
Published: (2018-03-01)

Inhibition of sodium glucose cotransporter 2 (SGLT2) delays liver fibrosis in a medaka model of nonalcoholic steatohepatitis (NASH)
by: Ryo Goto, et al.
Published: (2019-04-01)

Effects of Fibrotic Tissue on Liver-targeted Hydrodynamic Gene Delivery
by: Yuji Kobayashi, et al.
Published: (2016-01-01)

HBx and YAP expression could promote tumor development and progression in HBV-related hepatocellular carcinoma
by: Chiyumi Oda, et al.
Published: (2022-12-01)

Inhibition of sodium‐glucose cotransporter 2 ameliorates renal injury in a novel medaka model of nonalcoholic steatohepatitis‐related kidney disease
by: Takuro Nagoya, et al.
Published: (2019-12-01)

Long-term efficacy and safety of nalfurafine hydrochloride on pruritus in chronic liver disease patients: Patient-reported outcome based analyses.
by: Kenya Kamimura, et al.
Published: (2017-01-01)

Platelet-rich plasma-derived extracellular vesicles improve liver cirrhosis in mice
by: Yuichirou Maeda, et al.
Published: (2024-06-01)

Human placental extract improves liver cirrhosis in mice with regulation of macrophages and senescent cells
by: Natsuki Ishikawa, et al.
Published: (2025-03-01)

Site-Specific Impact of a Regional Hydrodynamic Injection: Computed Tomography Study during Hydrodynamic Injection Targeting the Swine Liver
by: Takeshi Yokoo, et al.
Published: (2015-09-01)

Renal Impairment in Chronic Hepatitis B: A Review
by: Hiroteru Kamimura, et al.
Published: (2018-06-01)

Dasatinib and Quercetin as Senolytic Drugs Improve Fat Deposition and Exhibit Antifibrotic Effects in the Medaka Metabolic Dysfunction-Associated Steatotic Liver Disease Model
by: Shunta Yakubo, et al.
Published: (2024-12-01)

Effective prevention of sorafenib-related vascular damage induced adverse events and maintenance of hepatic function by dried bonito broth and histidine
by: Sakai N, et al.
Published: (2019-05-01)

Fibrotic Burden in the Liver Differs Across Metabolic Dysfunction-Associated Fatty Liver Disease Subtypes
by: Tae Seop Lim, et al.
Published: (2023-07-01)

Establishment of a pancreatic cancer animal model using the pancreas-targeted hydrodynamic gene delivery method
by: Osamu Shibata, et al.
Published: (2022-06-01)

Repurposable Drugs for Immunotherapy and Strategies to Find Candidate Drugs
by: Norihiro Sakai, et al.
Published: (2023-08-01)

The expanding role of fish models in understanding non-alcoholic fatty liver disease
by: Yoichi Asaoka, et al.
Published: (2013-07-01)

The expanding role of fish models in understanding non-alcoholic fatty liver disease
by: Yoichi Asaoka, et al.
Published: (2014-03-01)

Endoscopic ultrasound-guided transmural drainage for subphrenic abscess: report of two cases and a literature review
by: Shinichi Morita, et al.
Published: (2018-04-01)

Evaluation of the effects of L-carnitine on medaka (Oryzias latipes) fatty liver
by: Koichi Fujisawa, et al.
Published: (2017-06-01)

Huge liver tumor in young man
by: Osamu Shibata, et al.
Published: (2020-04-01)

Maid gene dysfunction promotes hyperobesity via the reduction of adipose tissue inflammation in Mc4r gene-deficient mice
by: Kyutaro Koyama, et al.
Published: (2024-09-01)

Longitudinal increase in albumin-bilirubin score is associated with non-malignancy-related mortality and quality of life in patients with liver cirrhosis.
by: Akira Sakamaki, et al.
Published: (2022-01-01)

Fibrotic Burden Determines Cardiovascular Risk among Subjects with Metabolic Dysfunction-Associated Fatty Liver Disease
by: Eugene Han, et al.
Published: (2022-09-01)

Diagnostic value of T2 relaxation time for hepatic iron grading in rat model of fatty and fibrotic liver.
by: Mingli Jin, et al.
Published: (2022-01-01)

Diagnostic value of T2 relaxation time for hepatic iron grading in rat model of fatty and fibrotic liver
by: Mingli Jin, et al.
Published: (2022-01-01)

Non-alcoholic fatty liver disease—A pilot study investigating early inflammatory and fibrotic biomarkers of NAFLD with alcoholic liver disease
by: Joanne Watt, et al.
Published: (2022-12-01)

Antiprogramed cell death‐1 therapy with microspheres for metastatic liver tumors
by: Hiroteru Kamimura, et al.
Published: (2019-12-01)

Efficacy and Safety of Pancreas-Targeted Hydrodynamic Gene Delivery in Rats
by: Kohei Ogawa, et al.
Published: (2017-12-01)

Serum Bile Acid, Vitamin E, and Serotonin Metabolites Are Associated With Future Liver‐Related Events in Nonalcoholic Fatty Liver Disease
by: Kara Wegermann, et al.
Published: (2021-04-01)

Liver injury indicators and subsequent cancer development among non‐fatty liver population
by: Hiroshi Ito, et al.
Published: (2023-06-01)

Comparison of fatty liver index with fibroscan in non-alcoholic fatty liver disease
by: Marium Ahmed, et al.
Published: (2024-04-01)

Fatty liver in a child: Looking beyond nonalcoholic fatty liver disease
by: Jaya Agarwal, et al.
Published: (2021-01-01)

Liver fatty acid composition in mice with or without nonalcoholic fatty liver disease
by: Wang Xin, et al.
Published: (2011-12-01)

Theabrownin inhibits obesity and non-alcoholic fatty liver disease in mice via serotonin-related signaling pathways and gut-liver axis
by: Hang-Yu Li, et al.
Published: (2023-10-01)

Sex differences in predicting dyslipidemia using polygenic risk score with fatty liver index and fibrotic nonalcoholic steatohepatitis index
by: Sei Kim, et al.
Published: (2025-03-01)

Liver regeneration in nonalcoholic fatty liver disease
by: Aldo Lagomarsino
Published: (2012-12-01)

Fatty Liver Index for Predicting Nonalcoholic Fatty Liver Disease in an Asymptomatic Korean Population
by: Eun-Ju Cho, et al.
Published: (2021-11-01)